Physician profile
Douglas B Smith
NPI 1407832025
$146,896.32
in general payments reported to CMS, 2019-2025
38 companies · $1,182 in 2025
The $1,182 reported for 2025 was more than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $94K · 2020: $27K · 2021: $4,485 · 2022: $15K · 2023: $3,499 · 2024: $2,133 · 2025: $1,182.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,769 · Honoraria: $1,800 · Education: $245.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,768.63 |
| Honoraria | $1,800.00 |
| Education | $244.98 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $42,276.12 | 2019-2025 | |
| United Rheumatology | $28,900.00 | 2019-2021 | |
| Lilly USA, LLC | $28,589.13 | 2019-2025 | Taltz |
| Janssen Biotech, INC. | $14,478.14 | 2019-2025 | Tremfya, Simponi Aria |
| E.R. Squibb & Sons, L.L.C. | $8,948.86 | 2019-2025 | Orencia |
| Janssen Scientific Affairs, LLC | $5,272.87 | 2019-2022 | |
| Mallinckrodt Enterprises LLC | $5,256.98 | 2019 | |
| Abbvie INC. | $5,008.09 | 2019-2025 | Rinvoq |
| Horizon Therapeutics Plc | $2,627.67 | 2019-2023 | Krystexxa |
| Amgen INC. | $1,417.11 | 2019-2025 | Krystexxa, Tavneos, Evenity |
| Glaxosmithkline, LLC. | $614.52 | 2019-2025 | Benlysta |
| Ucb, INC. | $594.90 | 2019-2025 | Bimzelx, Cimzia |
| Mallinckrodt Hospital Products INC. | $526.41 | 2020-2025 | Acthar |
| Boehringer Ingelheim Pharmaceuticals, INC. | $374.90 | 2021-2025 | Cyltezo, Ofev, Spevigo |
| Aurinia Pharma U.S., INC. | $296.89 | 2022-2024 | Lupkynis |
Show all 38 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Douglas Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.